US$ 25.77
tirzepatide 2.5mg vial Flex-Dose 2 mL Injectable 10 mg/mL 2.5Mg Tirzepatide Injection - Physical
Description
Will my insurance cover these weight loss medications

Semaglutide has the strongest cardiovascular outcome data of any GLP-1 medication, with the SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes

The same 10 mg vial reconstituted with 2 mL yields 5 mg/mL

Your care team can adjust your plan at any time if needed

The JAMA Psychiatry 2025 semaglutide RCT in alcohol use disorder and observational data showing 50 to 56% lower AUD risk both point the same direction
